Exhibit 10.2


 


AMENDMENT TO EMPLOYMENT AGREEMENT


 


This Amendment to Employment
Agreement, dated as of January 1, 2023 (the “Amendment”), is made to that certain Employment Agreement (the “Agreement”),
dated as of July 1, 2022, between Dominari Holdings Inc. f/k/a AIkido Pharma Inc. (the “Corporation”), and Christopher
Devall (the “Executive”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in
the Agreement.


 


WHEREAS, Section 2
of the Agreement provides that on July 1, 2024, the Executive shall become the Chief Operating Officer of the Corporation;


 


WHEREAS, the Corporation
wishes to appoint the Executive as Chief Operating Officer of the Corporation on January 1, 2023;


 


WHEREAS, Section 4(a)
of the Agreement provides that on July 1, 2024, the Executive’s salary shall be $350,000 per annum;


 


WHEREAS, the Corporation
wishes to increase the Executive’s salary to $350,000 per annum effective January 1, 2023;


 


WHEREAS, effective
December 22, 2022, the Corporation changed its legal name from AIkido Pharma Inc. to Dominari Holdings Inc.


 


NOW, THEREFORE,
the Company and the Executive hereby agree as follows:


 


		1.	The first sentence of Section 2 of the Agreement is hereby amended to read as follows: “The
                                                          Executive shall serve as the Chief Operating Officer of the Corporation, effective as of January 1, 2023, with such duties,
                                                          responsibilities, and authority as are commensurate and consistent with his position, and such other duties, responsibilities and
                                                          authority as may be, from time to time, reasonably assigned to him by the Chief Executive Officer (“CEO”) or the
                                                          Board of Directors (the “Board”) of the Corporation.”



 


		2.	Section 4(a) of the Agreement is hereby amended to read as follows: “The Corporation shall pay
the Executive as compensation for his services hereunder, in equal semi-monthly or bi-weekly installments, the sum of $350,000 per annum
(as in effect from time to time, the “Base Salary”), less such deductions as shall be required to be withheld by applicable
law and regulations, effective January 1, 2023, and for the remainder of the Term, provided that the Corporation shall have the right
but not the obligation to increase the Base Salary.”



 


		3.	All references to “AIkido Pharma, Inc.” in the Agreement are amended to read as “Dominari
Holdings Inc.”



 


Except as specifically provided
herein, the terms and conditions of the Agreement shall remain in full force and effect and the rights and obligations of the parties
thereunder shall, except as specifically provided herein, be unaffected by this Amendment and shall continue as provided in such documents
and shall not be in any way changed, modified or superseded by the terms set forth herein. This Amendment may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same agreement.


 


[signature page follows]


 




     


     


    

 


IN WITNESS WHEREOF, this agreement is executed
as of the date first set forth above.


 


	 	DOMINARI HOLDINGS INC.
	 	 	 
	 	By: 	/s/ Anthony Hayes
	 	Name: 	Anthony Hayes
	 	Title: 	Chief Executive Officer
	 	 	 
	 	
	 	 	 
	 	By: 	/s/ Christopher Devall
	 		Christopher Devall